SAN FRANCISCO, CA – October 27, 2025 – Aizon, the leader in GxP Intelligent Manufacturing solutions, today pre-announced a significant upgrade to its core platform, integrating advanced Agentic AI. The new capabilities, available to all customers in early Q1, 2026, establish a new paradigm for how pharmaceutical and biotech professionals interact with manufacturing data, moving from traditional data management to autonomous insight generation and execution.
This launch is positioned to be a pivotal step in the democratization of GxP analytics, effectively putting the power of advanced data analysis directly into the hands of manufacturing, quality, and technical operations professionals. The enhancements empower end-users to instantly surface insights and dedicate their expertise to optimizing manufacturing outcomes—accelerating critical processes like yield improvement, faster deviation investigations, and expedited batch release.
Technical Leap: AI-Driven Analytics Creation
Analytics through Conversation
The newly enhanced platform leverages Agentic AI to translate user intent expressed through natural language into fully functional analytics applications.
This capability eliminates the time-consuming processes of data preparation and manual querying. Instead, users can converse with the platform to instantly generate complex tools like batch release cockpits, OEE trackers, and Product Quality Review (PQR) templates. By reducing the time required to build and adapt analytical tools from days to mere seconds, Aizon is fundamentally shifting the focus of experts from data handling to continuous process improvement.
Conversational Insights and GxP Governance
The upcoming enhancements introduce conversational data exploration, making it possible to instantly understand complex production trends and the outputs of advanced AI models simply by asking questions in natural language. Furthermore, the release significantly enhances the platform’s GMP AI Industrialization capabilities, providing robust governance and enhanced management tools that enable teams to seamlessly deploy and scale AI models within the demanding GxP regulatory framework.
Industry Impact: Humans Driving Evolution
“For more than a decade, my Co-Founder and Chief Compliance Officer, Dr. Toni Manzano, and I have pursued a clear vision: that the future of pharmaceutical manufacturing would be driven by data,” said Pep Gubau, Founder and CEO of Aizon. “From day one, our mission has been to build the technology that enables Pharma and Biotech companies to fully leverage GxP AI. We’ve worked hand in hand with regulatory agencies and leading industry associations to promote the safe and effective adoption of AI in regulated environments. Today, with Agentic AI, we are realizing that vision at every level, from leadership to the shop floor, empowering the industry to deliver medicines to patients faster, with higher quality, and at lower cost.”
“This release represents a turning point for the pharmaceutical industry,” said Geri Studebaker, Chief Commercial Officer at Aizon. “By bringing natural language and Agentic AI into GxP analytics, we are removing the traditional barriers between manufacturing data and the intelligence needed to act on it. This is how GxP manufacturing evolves: with humans driving process improvement and AI serving as the intelligence engine doing the heavy lifting.”
Ms. Studebaker, who previously served as Head of Sales for Life Sciences at Google Cloud, emphasized the importance of adopting transformative technologies safely, noting that these capabilities were developed in close collaboration with select pharmaceutical partners to ensure alignment with regulatory and quality standards.
Aizon is committed to advancing the future of GxP Intelligent Manufacturing by delivering an AI software platform that transforms how pharmaceutical and biotech companies use data to achieve operational excellence, reduce quality issues, and accelerate time-to-market.
